^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

alsevalimab (FPA150)

i
Other names: FPA150, FPA 150
Associations
Company:
Amgen
Drug class:
B7-H4 inhibitor
Associations
27d
FPA150-001: FPA150 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=95, Terminated, Five Prime Therapeutics, Inc. | Phase classification: P1a/1b --> P1 | Completed --> Terminated; The Sponsor terminated the study for reasons unrelated to safety.
Phase classification • Trial termination • Metastases
|
VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1)
|
VTCN1 underexpression
|
Keytruda (pembrolizumab) • alsevalimab (FPA150)
almost3years
FPA150-001: FPA150 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1a/1b, N=95, Completed, Five Prime Therapeutics, Inc. | Active, not recruiting --> Completed | N=278 --> 95 | Trial completion date: Jan 2022 --> May 2021 | Trial primary completion date: Jan 2022 --> May 2021
Clinical • Trial completion • Enrollment change • Trial completion date • Trial primary completion date
|
VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1)
|
VTCN1 underexpression
|
Keytruda (pembrolizumab) • alsevalimab (FPA150)